SEC Filings

Form 424B5
ARRAY BIOPHARMA INC filed this Form 424B5 on 09/15/2017
Document Outline
Entire Document (547.4 KB)
Subdocument 1 - 424B5 - 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - Filed Pursuant to Rule 424(b)(5)
Page 3 - Table of contents
Page 4 - About this prospectus supplement
Page 5 - Prospectus supplement summary
Page 6 - Binimetinib and encorafenib
Page 7 - Pierre Fabre agreement
Page 8 - Ono agreement
Page 9 - COLUMBUS
Page 10 - COLUMBUS Part 2:
Page 11 - BEACON CRC
Page 12 - Bristol-Myers Squibb collaboration
Page 13 - SECOMBIT
Page 14 - ARRY-797
Page 15 - The offering
Page 16 - Risk factors
Page 17 - Because we do not intend to pay dividends, stockholders will benefit from an investment in our commo
Page 18 - We have broad discretion in the use of the net proceeds from this offering, and we may not use these
Page 19 - Forward-looking statements
Page 20 - Use of proceeds
Page 21 - Dilution
Page 22 - Price range of our common stock
Page 23 - Dividend policy
Page 24 - Material U.S. federal tax considerations to non-U.S. holders
Page 25 - If you are considering the purchase of our common stock, you should consult your own tax advisors co
Page 26 - Gain on disposition of common stock
Page 27 - Federal estate tax
Page 28 - THE PRECEDING DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY A
Page 29 - Underwriting
Page 30 - N/A
Page 31 - N/A
Page 32 - Selling restrictions
Page 33 - Notice to prospective investors in the European Economic Area
Page 34 - Notice to prospective investors in Switzerland
Page 35 - Notice to prospective investors in Hong Kong
Page 36 - Notice to prospective investors in Singapore
Page 37 - Where you can find more information
Page 38 - http://www.arraybiopharma.com
Page 39 - PROSPECTUS
Page 40 - TABLE OF CONTENTS
Page 41 - ABOUT THIS PROSPECTUS
Page 42 - ABOUT ARRAY BIOPHARMA
Page 43 - USE OF PROCEEDS
Page 44 - Listing
Page 45 - N/A
Page 46 - Limitation of Liability of Directors
Page 47 - Staggered Board
Page 48 - Authorized but Unissued Shares
Page 49 - Dividends and Other Distributions
Page 50 - Conversion of Preferred Stock
Page 51 - Resignation and Removal of Depositary
Page 52 - N/A
Page 53 - Conversion or Exchange Rights
Page 54 - Discharge, Defeasance and Covenant Defeasance
Page 55 - Modification of the Indenture
Page 56 - N/A
Page 57 - Registered Global Securities and Book Entry System
Page 58 - N/A
Page 59 - Concerning the Trustee
Page 60 - Exercise of Warrants
Page 61 - Enforceability of Rights of Holders of Warrants
Page 62 - Issuance in Series
Page 63 - Street Name Holders
Page 64 - Special Considerations For Indirect Holders
Page 65 - Special Situations When A Global Security Will Be Terminated
Page 66 - PLAN OF DISTRIBUTION
Page 67 - Underwriters.
Page 68 - Passive Market Making.
Page 69 - INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Page 70 - 20,930,232 shares